BR112017020016A2 - formas de sal farmacêutico de um inibidor de amina oxidase sensível a semicarbazida (ssao) - Google Patents

formas de sal farmacêutico de um inibidor de amina oxidase sensível a semicarbazida (ssao)

Info

Publication number
BR112017020016A2
BR112017020016A2 BR112017020016A BR112017020016A BR112017020016A2 BR 112017020016 A2 BR112017020016 A2 BR 112017020016A2 BR 112017020016 A BR112017020016 A BR 112017020016A BR 112017020016 A BR112017020016 A BR 112017020016A BR 112017020016 A2 BR112017020016 A2 BR 112017020016A2
Authority
BR
Brazil
Prior art keywords
ssao
salt forms
oxidase inhibitor
pharmaceutical salt
amine oxidase
Prior art date
Application number
BR112017020016A
Other languages
English (en)
Inventor
Savory Edward
Higginbottom Michael
Original Assignee
Proximagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proximagen Ltd filed Critical Proximagen Ltd
Publication of BR112017020016A2 publication Critical patent/BR112017020016A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

a presente invenção refere-se a sais de mesilato e sulfato de mesilato de (4s)-4-isopropil-1,4,6,7-tetra-hidro-5h-imidazo[4,5-c]¬piridina-5-carboxilato de (3s)-tetra-hidrofuran-3-ila, e hidratos dos mesmos, e seu uso em medicina.
BR112017020016A 2015-04-24 2016-04-22 formas de sal farmacêutico de um inibidor de amina oxidase sensível a semicarbazida (ssao) BR112017020016A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1507031.1A GB201507031D0 (en) 2015-04-24 2015-04-24 New pharmaceutical salt forms
PCT/GB2016/051119 WO2016170351A1 (en) 2015-04-24 2016-04-22 Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (ssao)

Publications (1)

Publication Number Publication Date
BR112017020016A2 true BR112017020016A2 (pt) 2018-06-19

Family

ID=53488629

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020016A BR112017020016A2 (pt) 2015-04-24 2016-04-22 formas de sal farmacêutico de um inibidor de amina oxidase sensível a semicarbazida (ssao)

Country Status (20)

Country Link
US (1) US10316034B2 (pt)
EP (1) EP3286190B1 (pt)
JP (2) JP2018513189A (pt)
KR (1) KR20170139045A (pt)
CN (2) CN112851669A (pt)
AR (1) AR104360A1 (pt)
AU (1) AU2016251707B2 (pt)
BR (1) BR112017020016A2 (pt)
CA (1) CA2979144A1 (pt)
DK (1) DK3286190T3 (pt)
EA (1) EA035668B1 (pt)
ES (1) ES2804155T3 (pt)
GB (1) GB201507031D0 (pt)
HK (1) HK1249906A1 (pt)
HU (1) HUE049985T2 (pt)
IL (1) IL254153A0 (pt)
MX (1) MX2017013049A (pt)
PT (1) PT3286190T (pt)
SG (1) SG11201707867WA (pt)
WO (1) WO2016170351A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201507036D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Crystalline enzyme inhibitor compound
GB201507048D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Treatment of pain
GB201618029D0 (en) 2016-10-25 2016-12-07 Proximagen Ltd New process
CN108017634A (zh) * 2017-12-15 2018-05-11 清华大学 一种制备吡咯并多环衍生物的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141899A (en) 1976-01-07 1979-02-27 Societa' Farmaceutici Italia S.P.A. 4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives
IT1098015B (it) 1978-08-07 1985-08-31 Farmaceutici Italia Nuovi 4,5,6,7,-tetraidroimidazo-aperta par.quadrata 4,5-c chiusa par.quadrata-piridin-derivati
JP2002542245A (ja) * 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 置換イミダゾール、それらの製造および使用
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
SE0004101D0 (sv) 2000-11-09 2000-11-09 Pharmacia Ab New use
AU2002214505A1 (en) * 2000-11-09 2002-05-21 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives
KR20060135781A (ko) * 2004-02-25 2006-12-29 라 졸라 파마슈티칼 컴파니 질병의 치료를 위한 아민 및 아미드
US20070066646A1 (en) 2005-08-02 2007-03-22 Genmedica Therapeutics Sl Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof
EP3461499A1 (en) 2006-06-07 2019-04-03 The Board of Trustees of The Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of recurrence of epileptic seizures
EP2328895B1 (en) * 2008-09-16 2013-03-27 Proximagen Limited Pyrazolo[4,3-c]pyridine compounds and their use as inhibitors of SSAO
AU2009294660B2 (en) * 2008-09-16 2013-11-14 Benevolentai Cambridge Limited New compounds I
GB201004311D0 (en) * 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
GB201115853D0 (en) * 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
AU2011376717A1 (en) * 2011-09-14 2014-03-20 Proximagen Limited New enzyme inhibitor compounds
GB201304526D0 (en) * 2013-03-13 2013-04-24 Proximagen Ltd New compounds
WO2014199171A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
EP3131539B1 (en) 2014-04-15 2018-12-05 Pécsi Tudományegyetem Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation
GB201507048D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Treatment of pain
GB201507036D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Crystalline enzyme inhibitor compound

Also Published As

Publication number Publication date
JP2018513189A (ja) 2018-05-24
US20180111928A1 (en) 2018-04-26
MX2017013049A (es) 2017-12-08
HK1249906A1 (zh) 2018-11-16
CA2979144A1 (en) 2016-10-27
EA201792121A1 (ru) 2018-03-30
WO2016170351A1 (en) 2016-10-27
JP2021073256A (ja) 2021-05-13
US10316034B2 (en) 2019-06-11
AR104360A1 (es) 2017-07-12
CN112851669A (zh) 2021-05-28
EA035668B1 (ru) 2020-07-23
DK3286190T3 (da) 2020-07-13
IL254153A0 (en) 2017-10-31
PT3286190T (pt) 2020-07-09
HUE049985T2 (hu) 2020-11-30
AU2016251707A1 (en) 2017-10-05
KR20170139045A (ko) 2017-12-18
AU2016251707B2 (en) 2020-02-20
GB201507031D0 (en) 2015-06-10
ES2804155T3 (es) 2021-02-04
EP3286190A1 (en) 2018-02-28
CN107531702A (zh) 2018-01-02
EP3286190B1 (en) 2020-06-03
SG11201707867WA (en) 2017-11-29

Similar Documents

Publication Publication Date Title
BR112016024545A2 (pt) derivados de pirazolo pirimidina e seu uso como inibidores de malt1
CY1119645T1 (el) Τριπεπτιδικοι αναστολεις πρωτεασης εποξειδικης κετονης
BR112017004141A2 (pt) ?sondas para imageamento de proteína de huntingtina?
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112017020016A2 (pt) formas de sal farmacêutico de um inibidor de amina oxidase sensível a semicarbazida (ssao)
CO7091182A2 (es) Inhibidores de beta-lactamasa isoxazol
BR112018068278A2 (pt) derivado de 3-desóxi e suas composições farmacêuticas
BR112016012465A8 (pt) sal, método de preparação do sal e composição farmacêutica
CL2016000556A1 (es) Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso.
BR112016008468A2 (pt) Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
EA201692285A8 (ru) Ингибиторы ezh2 для лечения лимфомы
EA201591752A1 (ru) Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы
BR112017019653A2 (pt) derivados heteroaril bicíclicos fundidos tendo atividade como inibidores de phd
BR112016008799A8 (pt) derivados de pirazolopirimidona ou pirrolotriazona, seus usos, seus processos para sua preparação e seus intermediários, e composição farmacêutica
BR112017004136A2 (pt) sondas para imageamento de proteína de huntingtina
EA029499B9 (ru) Ингибиторы rorc2 и способы их применения
BR112017004134A2 (pt) ?sondas para imageamento de proteína de huntingtina?
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
BR112017004140A2 (pt) sondas para imageamento de proteína de huntingtina
BR112017019337A2 (pt) tratamento de dor
BR112017017835A2 (pt) inibidores de grelina o-acil transferase
ITUA20161302A1 (it) "dispositivo di rotazione e posizionamento in particolare per oggetti globosi"
BR112014028121A2 (pt) n-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida
BR112017004000A2 (pt) formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3-carboxamida
BR112017018342A2 (pt) inibidores de grelina o-acil transferase

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BENEVOLENTAI CAMBRIDGE LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: BENEVOLENTAI CAMBRIDGE LIMITED (GB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2719 DE 14-02-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.